Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov;39(11):1784-95.
doi: 10.1007/s00259-012-2178-9. Epub 2012 Jul 17.

Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease

Anniina Snellman  1 , Johanna Rokka, Francisco R Lopez-Picon, Olli Eskola, Ian Wilson, Gill Farrar, Mika Scheinin, Olof Solin, Juha O Rinne, Merja Haaparanta-Solin
Affiliations

Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease

Anniina Snellman et al. Eur J Nucl Med Mol Imaging. 2012 Nov.

Abstract

Purpose: The aim of this study was to investigate the potential of [(18)F]flutemetamol as a preclinical PET tracer for imaging β-amyloid (Aβ) deposition by comparing its pharmacokinetics to those of [(11)C]Pittsburgh compound B ([(11)C]PIB) in wild-type Sprague Dawley rats and C57Bl/6N mice. In addition, binding of [(18)F]flutemetamol to Aβ deposits was studied in the Tg2576 transgenic mouse model of Alzheimer's disease.

Methods: [(18)F]Flutemetamol biodistribution was evaluated using ex vivo PET methods and in vivo PET imaging in wild-type rats and mice. Metabolism and binding of [(11)C]PIB and [(18)F]flutemetamol to plasma proteins were analysed using thin-layer chromatography and ultrafiltration methods, respectively. Radiation dose estimates were calculated from rat ex vivo biodistribution data. The binding of [(18)F]flutemetamol to Aβ deposits was also studied using ex vivo and in vitro autoradiography. The location of Aβ deposits in the brain was determined with thioflavine S staining and immunohistochemistry.

Results: The pharmacokinetics of [(18)F]flutemetamol resembled that of [(11)C]PIB in rats and mice. In vivo studies showed that both tracers readily entered the brain, and were excreted via the hepatobiliary pathway in both rats and mice. The metabolism of [(18)F]flutemetamol into radioactive metabolites was faster than that of [(11)C]PIB. [(18)F]Flutemetamol cleared more slowly from the brain than [(11)C]PIB, particularly from white matter, in line with its higher lipophilicity. Effective dose estimates for [(11)C]PIB and [(18)F]flutemetamol were 2.28 and 6.65 μSv/MBq, respectively. Autoradiographs showed [(18)F]flutemetamol binding to fibrillar Aβ deposits in the brain of Tg2576 mice.

Conclusion: Based on its pharmacokinetic profile, [(18)F]flutemetamol showed potential as a PET tracer for preclinical imaging. It showed good brain uptake and was bound to Aβ deposits in the brain of Tg2576 mice. However, its high lipophilicity might complicate the analysis of PET data, particularly in small-animal imaging.

PubMed Disclaimer

References

    1. Acta Neuropathol. 2009 Jul;118(1):5-36 - PubMed
    1. J Alzheimers Dis. 2010;20(1):113-26 - PubMed
    1. J Nucl Med. 2010 Jun;51(6):913-20 - PubMed
    1. J Med Chem. 2003 Jun 19;46(13):2740-54 - PubMed
    1. Ann Neurol. 2010 Sep;68(3):319-29 - PubMed

Publication types

LinkOut - more resources